<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206517</url>
  </required_header>
  <id_info>
    <org_study_id>P06522</org_study_id>
    <nct_id>NCT01206517</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)</brief_title>
  <official_title>A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, sequential-group, two site, multiple dose escalating study of
      sublingual administered asenapine in a pediatric population with schizophrenia or bipolar I
      disorder; in one study cohort (3a) participants with other conditions treatable with chronic
      antipsychotic medication can also be enrolled. Participants will receive a single sublingual
      placebo dose on Day -1, followed by multiple sublingual doses of asenapine twice daily
      (b.i.d.) for 6 days (Cohorts 1 and 2), 7 days (Cohort 3b-d), or 11 days (Cohort 3a), and a
      final once daily administration on Day 7 (Cohorts 1 and 2), Day 8 (Cohort 3b-d) or Day 12
      (Cohort 3a).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2010</start_date>
  <completion_date type="Actual">August 4, 2011</completion_date>
  <primary_completion_date type="Actual">August 4, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Asenapine</measure>
    <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
    <description>Cmax is the peak plasma concentration following a dose of the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Asenapine</measure>
    <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
    <description>tmax is the time from dosing to maximum plasma drug concentration levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post Dose (AUC0-12) of Asenapine</measure>
    <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6 and 12 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
    <description>AUC0-12 is the area under the plasma drug-concentration time curve calculated for the 12 hour interval after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase (Elimination) Half-life (t1/2) of Asenapine</measure>
    <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
    <description>Elimination t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 10 or 11 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 10 or 11 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a-d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3a: Participants 10 or 11 years of age
Cohort 3b: Participants 12 or 13 years of age
Cohort 3c: Participants 14 or 15 years of age
Cohort 3d: Participants 16 or 17 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 2.5 mg</intervention_name>
    <description>Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>SCH 900274</other_name>
    <other_name>Org 5222</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 5 mg</intervention_name>
    <description>Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>SCH 900274</other_name>
    <other_name>Org 5222</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 10 mg</intervention_name>
    <description>Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.</description>
    <arm_group_label>Cohort 3a-d</arm_group_label>
    <other_name>SCH 900274</other_name>
    <other_name>Org 5222</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        For participants in Cohorts 1, 2, 3b, 3c and 3d:

          -  Diagnosis of schizophrenia or bipolar I disorder

          -  A schizophrenic participant must have a diagnosis of current schizophrenia of paranoid
             disorganized, catatonic, or undifferentiated subtype as determined by a structured
             clinical interview at screening

          -  A bipolar I disorder participant must have a primary diagnosis of bipolar I disorder,
             current episode manic, or mixed as determined by a structured clinical interview at
             screening

        For participants in Cohort 3a:

          -  Documented history of schizophrenia, bipolar disorder, autism, conduct disorder,
             oppositional defiant disorder, or any condition for which the chronic use of
             antipsychotic medication (e.g, risperidone, olanzapine, aripiprazole, haloperidol) was
             warranted and/or administered

        All participants:

          -  Must be at least 10 and not older than 17 years of age at the day of first asenapine
             dosing (Cohort 3); for Cohort 1 and 2 subjects should be at least 10 and not older
             than 11 years of age at the day of first asenapine dosing

          -  Must be able and willing to sign an informed assent as required by local regulations
             before study participation and able to adhere to dose and visit schedules or their
             parent/authorized legal representative(s) should be able and willing to sign an
             informed consent, and should be fluent in the language of the informed consent

          -  Must have a caregiver or an identified responsible person who is considered reliable
             by the investigator and who has agreed to provide support to the subject to ensure
             compliance with trial treatment, outpatient visits, and protocol procedures

          -  Must be fluent in the language of the investigator, trial staff (including raters) and
             the informed assent

          -  Must be willing to discontinue all psychotropic medication during the treatment period
             except for those specified in the protocol

          -  Have discontinued the use of strong inhibitors or inducers of cytochrome P450 (CYP)1A2
             and/or CYP2D6 (e.g. fluvoxamine, citalopram, fluoxetine, paroxetine, omeprazole, and
             rifampicin) and beta-blockers, applying a washout period of 5 half lives or 7 days,
             whichever is longer, AND be stabilized on non-interacting alternative medication (i.e.
             medication not interacting with asenapine pharmacokinetics) for 2 weeks prior to
             baseline if their medical condition requires this

          -  Clinical laboratory tests (complete blood count [CBC], blood chemistry, and
             urinalysis) must be within normal limits or clinically acceptable to the investigator,
             after discussion with the Sponsor and following agreement of the Sponsor's medical
             monitor

          -  Screening 12 lead electrocardiogram (ECG) conduction intervals and vital signs
             recordings (oral body temperature, systolic/diastolic blood pressure and pulse rate)
             must be clinically acceptable according to the investigator, after discussion with the
             Sponsor and following agreement of the Sponsor's medical monitor

          -  If male, and non-vasectomized, must agree to use a condom with spermicide (when
             marketed in the country) or abstain from sexual intercourse, during the trial and for
             3 months after stopping the medication

        Female participants must:

        If unsterilized, have used a medically accepted method of contraception for 3 months (or
        abstained from sexual intercourse) prior to the screening period, and agree to use a
        medically accepted method of contraception during the trial (including the screening period
        prior to receiving trial medication) and for 2 months after stopping the trial medication.
        An acceptable method of contraception includes one of the following:

          -  stable oral, transdermal, injectable, or sustained-release vaginal hormonal
             contraceptive regimen without breakthrough uterine bleeding for 3 months prior to
             Screening; in addition, during study use of condom and/or spermicide (when marketed in
             the country)

          -  intrauterine device (inserted at least 2 months prior to Screening visit); in
             addition, during study use of condom and/or spermicide (when marketed in the country)

        Note: Vasectomy of the partner is not considered sufficient contraception and one of the 2
        methods listed above must be used

        Females who are not currently sexually active must also consent to use one of these
        accepted methods of contraception should they become sexually active while participating in
        the study

          -  condom (male or female) with spermicide (when marketed within the country),

          -  diaphragm or cervical cap with spermicide (when marketed within the country) and
             condom (male),

        Exclusion Criteria

        The participant will be excluded from entry if ANY of the criteria listed below are met at
        baseline

        The participant:

          -  Is pregnant, intends to become pregnant (within 3 months of ending the study), or is
             breastfeeding

          -  In the opinion of the investigator, will not be able to participate optimally in the
             study

          -  Has an uncontrolled, unstable clinically significant medical condition (e.g., renal,
             endocrine, hepatic, respiratory, cardiovascular, hematologic, immunologic,
             gastrointestinal or cerebrovascular disease, or malignancy) that may interfere with
             the interpretation of pharmacokinetic, safety and tolerability evaluations in the
             opinion of the investigator

          -  Has a history of any infectious disease within 4 weeks prior to drug administration
             that in the opinion of the investigator, affects the subject's ability to participate
             in the trial

          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies or human
             immunodeficiency virus (HIV)

          -  Has a positive screen for drugs with a high potential for abuse (during the Screening
             period or clinical conduct of the trial)

          -  Has a history of psychiatric or personality disorders that in the opinion of the
             investigator and sponsor, affects the subject's ability to participate in the trial

          -  Has a history of neuroleptic malignant syndrome

          -  Has a diagnosis of mental retardation or organic brain disorder

          -  Has a primary diagnosis other than schizophrenia or bipolar I disorder, current
             episode manic or mixed, that is primarily responsible for current symptoms and
             functional impairment; this exclusion is not applicable to participants in Cohort 3a

          -  Has a diagnosis of psychotic disorder or a behavioral disturbance thought to be
             substance induced or due to substance abuse

          -  Has a current (past 6 months) substance and alcohol abuse or dependence (excluding
             nicotine and caffeine)

          -  Has a history of tardive dyskinesia or tardive dystonia

          -  If has attention-deficit/hyperactivity disorder (ADHD), has not been on a stable dose
             of stimulants (e.g. amphetamines, methylphenidate) for the last 3 months (participants
             who have not taken any stimulants in the last month will not be excluded)

          -  Has a history of alcohol or drug abuse in the past 2 years

          -  Has donated blood in the past 60 days

          -  Has previously received asenapine

          -  Is at imminent risk of self-harm or harm to others, in the investigator's opinion
             based on clinical judgment

          -  Report at Screening, suicidal ideation, or suicidal behavior in the past 6 months

          -  Is currently participating in another clinical study or have participated in a
             clinical study (e.g., laboratory or clinical evaluation) within 30 days of baseline

          -  Is part of the study staff personnel or family members of the study staff personnel

          -  Has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic
             episodes) which, in the opinion of the investigator and sponsor, interfere with their
             ability to participate in the trial

          -  Smokes more than 10 cigarettes or equivalent tobacco use per day

          -  Has a history of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <results_first_submitted>November 20, 2012</results_first_submitted>
  <results_first_submitted_qc>November 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2012</results_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asenapine</keyword>
  <keyword>pediatric schizophrenia</keyword>
  <keyword>bipolar I disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Asenapine 2.5 mg - Cohort 1</title>
          <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-6 and a single asenapine 2.5 mg dose in the morning on Day 7</description>
        </group>
        <group group_id="P2">
          <title>Asenapine 5 mg - Cohort 2</title>
          <description>Participants 10 or 11 years of age; administered asenapine 5 mg b.i.d on Days 1-6 and a single asenapine 5 mg dose in the morning on Day 7</description>
        </group>
        <group group_id="P3">
          <title>Asenapine 10 mg - Cohort 3a</title>
          <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-3, asenapine 2.5 mg in the morning and 5 mg in the evening on Day 4, asenapine 5 mg b.i.d. on Days 5-6, asenapine 5 mg in the morning and 10 mg in the evening on Day 7, asenapine 10 mg b.i.d on Days 8-11, and a single asenapine 10 mg dose in the morning on Day 12</description>
        </group>
        <group group_id="P4">
          <title>Asenapine 10 mg - Cohort 3b</title>
          <description>Participants 12 or 13 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
        </group>
        <group group_id="P5">
          <title>Asenapine 10 mg - Cohort 3c</title>
          <description>Participants 14 or 15 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
        </group>
        <group group_id="P6">
          <title>Asenapine 10 mg - Cohort 3d</title>
          <description>Participants 16 or 17 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Asenapine 2.5 mg - Cohort 1</title>
          <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-6 and a single asenapine 2.5 mg dose in the morning on Day 7</description>
        </group>
        <group group_id="B2">
          <title>Asenapine 5 mg - Cohort 2</title>
          <description>Participants 10 or 11 years of age; administered asenapine 5 mg b.i.d on Days 1-6 and a single asenapine 5 mg dose in the morning on Day 7</description>
        </group>
        <group group_id="B3">
          <title>Asenapine 10 mg - Cohort 3a</title>
          <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-3, asenapine 2.5 mg in the morning and 5 mg in the evening on Day 4, asenapine 5 mg b.i.d. on Days 5-6, asenapine 5 mg in the morning and 10 mg in the evening on Day 7, asenapine 10 mg b.i.d on Days 8-11, and a single asenapine 10 mg dose in the morning on Day 12</description>
        </group>
        <group group_id="B4">
          <title>Asenapine 10 mg - Cohort 3b</title>
          <description>Participants 12 or 13 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
        </group>
        <group group_id="B5">
          <title>Asenapine 10 mg - Cohort 3c</title>
          <description>Participants 14 or 15 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
        </group>
        <group group_id="B6">
          <title>Asenapine 10 mg - Cohort 3d</title>
          <description>Participants 16 or 17 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="0.4"/>
                    <measurement group_id="B2" value="10.5" spread="0.8"/>
                    <measurement group_id="B3" value="10.3" spread="0.5"/>
                    <measurement group_id="B4" value="12.5" spread="0.6"/>
                    <measurement group_id="B5" value="14.5" spread="0.6"/>
                    <measurement group_id="B6" value="16.5" spread="0.6"/>
                    <measurement group_id="B7" value="12.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Asenapine</title>
        <description>Cmax is the peak plasma concentration following a dose of the study drug.</description>
        <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
        <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 2.5 mg - Cohort 1</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-6 and a single asenapine 2.5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 5 mg - Cohort 2</title>
            <description>Participants 10 or 11 years of age; administered asenapine 5 mg b.i.d on Days 1-6 and a single asenapine 5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O3">
            <title>Asenapine 10 mg - Cohort 3a</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-3, asenapine 2.5 mg in the morning and 5 mg in the evening on Day 4, asenapine 5 mg b.i.d. on Days 5-6, asenapine 5 mg in the morning and 10 mg in the evening on Day 7, asenapine 10 mg b.i.d on Days 8-11, and a single asenapine 10 mg dose in the morning on Day 12</description>
          </group>
          <group group_id="O4">
            <title>Asenapine 10 mg - Cohort 3b</title>
            <description>Participants 12 or 13 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O5">
            <title>Asenapine 10 mg - Cohort 3c</title>
            <description>Participants 14 or 15 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O6">
            <title>Asenapine 10 mg - Cohort 3d</title>
            <description>Participants 16 or 17 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Asenapine</title>
          <description>Cmax is the peak plasma concentration following a dose of the study drug.</description>
          <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="1.17"/>
                    <measurement group_id="O2" value="3.48" spread="0.629"/>
                    <measurement group_id="O3" value="9.24" spread="5.17"/>
                    <measurement group_id="O4" value="6.75" spread="0.701"/>
                    <measurement group_id="O5" value="6.98" spread="6.46"/>
                    <measurement group_id="O6" value="7.87" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Asenapine</title>
        <description>tmax is the time from dosing to maximum plasma drug concentration levels.</description>
        <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
        <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 2.5 mg - Cohort 1</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-6 and a single asenapine 2.5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 5 mg - Cohort 2</title>
            <description>Participants 10 or 11 years of age; administered asenapine 5 mg b.i.d on Days 1-6 and a single asenapine 5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O3">
            <title>Asenapine 10 mg - Cohort 3a</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-3, asenapine 2.5 mg in the morning and 5 mg in the evening on Day 4, asenapine 5 mg b.i.d. on Days 5-6, asenapine 5 mg in the morning and 10 mg in the evening on Day 7, asenapine 10 mg b.i.d on Days 8-11, and a single asenapine 10 mg dose in the morning on Day 12</description>
          </group>
          <group group_id="O4">
            <title>Asenapine 10 mg - Cohort 3b</title>
            <description>Participants 12 or 13 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O5">
            <title>Asenapine 10 mg - Cohort 3c</title>
            <description>Participants 14 or 15 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O6">
            <title>Asenapine 10 mg - Cohort 3d</title>
            <description>Participants 16 or 17 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Asenapine</title>
          <description>tmax is the time from dosing to maximum plasma drug concentration levels.</description>
          <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.5" upper_limit="1.5"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O5" value="0.5" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0.5" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post Dose (AUC0-12) of Asenapine</title>
        <description>AUC0-12 is the area under the plasma drug-concentration time curve calculated for the 12 hour interval after dosing.</description>
        <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6 and 12 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
        <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 2.5 mg - Cohort 1</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-6 and a single asenapine 2.5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 5 mg - Cohort 2</title>
            <description>Participants 10 or 11 years of age; administered asenapine 5 mg b.i.d on Days 1-6 and a single asenapine 5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O3">
            <title>Asenapine 10 mg - Cohort 3a</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-3, asenapine 2.5 mg in the morning and 5 mg in the evening on Day 4, asenapine 5 mg b.i.d. on Days 5-6, asenapine 5 mg in the morning and 10 mg in the evening on Day 7, asenapine 10 mg b.i.d on Days 8-11, and a single asenapine 10 mg dose in the morning on Day 12</description>
          </group>
          <group group_id="O4">
            <title>Asenapine 10 mg - Cohort 3b</title>
            <description>Participants 12 or 13 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O5">
            <title>Asenapine 10 mg - Cohort 3c</title>
            <description>Participants 14 or 15 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O6">
            <title>Asenapine 10 mg - Cohort 3d</title>
            <description>Participants 16 or 17 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post Dose (AUC0-12) of Asenapine</title>
          <description>AUC0-12 is the area under the plasma drug-concentration time curve calculated for the 12 hour interval after dosing.</description>
          <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="6.10"/>
                    <measurement group_id="O2" value="23.6" spread="4.02"/>
                    <measurement group_id="O3" value="55.2" spread="20.9"/>
                    <measurement group_id="O4" value="41.3" spread="9.59"/>
                    <measurement group_id="O5" value="36.5" spread="36.7"/>
                    <measurement group_id="O6" value="41.8" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase (Elimination) Half-life (t1/2) of Asenapine</title>
        <description>Elimination t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase.</description>
        <time_frame>Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)</time_frame>
        <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 2.5 mg - Cohort 1</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-6 and a single asenapine 2.5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 5 mg - Cohort 2</title>
            <description>Participants 10 or 11 years of age; administered asenapine 5 mg b.i.d on Days 1-6 and a single asenapine 5 mg dose in the morning on Day 7</description>
          </group>
          <group group_id="O3">
            <title>Asenapine 10 mg - Cohort 3a</title>
            <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-3, asenapine 2.5 mg in the morning and 5 mg in the evening on Day 4, asenapine 5 mg b.i.d. on Days 5-6, asenapine 5 mg in the morning and 10 mg in the evening on Day 7, asenapine 10 mg b.i.d on Days 8-11, and a single asenapine 10 mg dose in the morning on Day 12</description>
          </group>
          <group group_id="O4">
            <title>Asenapine 10 mg - Cohort 3b</title>
            <description>Participants 12 or 13 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O5">
            <title>Asenapine 10 mg - Cohort 3c</title>
            <description>Participants 14 or 15 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
          <group group_id="O6">
            <title>Asenapine 10 mg - Cohort 3d</title>
            <description>Participants 16 or 17 years of age; administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase (Elimination) Half-life (t1/2) of Asenapine</title>
          <description>Elimination t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase.</description>
          <population>All participants administered asenapine with evaluable pharmacokinetic data. Two participants in Cohort 3a and one participant in Cohort 3c did not complete the study and are excluded from pharmacokinetic analysis.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="6.12"/>
                    <measurement group_id="O2" value="18.5" spread="3.11"/>
                    <measurement group_id="O3" value="15.9" spread="2.34"/>
                    <measurement group_id="O4" value="16.5" spread="3.38"/>
                    <measurement group_id="O5" value="24.3" spread="14.9"/>
                    <measurement group_id="O6" value="24.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 14</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Asenapine 2.5 mg - Cohort 1</title>
          <description>Participants 10 or 11 years of age; administered asenapine 2.5 mg b.i.d on Days 1-6 and a single asenapine 2.5 mg dose in the morning on Day 7</description>
        </group>
        <group group_id="E2">
          <title>Asenapine 5 mg - Cohort 2</title>
          <description>Participants 10 or 11 years of age; administered asenapine 5 mg b.i.d on Days 1-6 and a single asenapine 5 mg dose in the morning on Day 7</description>
        </group>
        <group group_id="E3">
          <title>Asenapine 10 mg - Cohort 3a-d</title>
          <description>Participants 10-17 years of age:
Participants 10 or 11 years of age (Cohort 3a); administered asenapine 2.5 mg b.i.d on Days 1-3, asenapine 2.5 mg in the morning and 5 mg in the evening on Day 4, asenapine 5 mg b.i.d. on Days 5-6, asenapine 5 mg in the morning and 10 mg in the evening on Day 7, asenapine 10 mg b.i.d on Days 8-11, and a single asenapine 10 mg dose in the morning on Day 12
Participants 12-17 years of age (Cohort 3b-d); administered asenapine 5 mg b.i.d on Day 1 (an additional day of 5 mg b.i.d could be allowed), asenapine 10 mg b.i.d on Days 2-7, and a single asenapine 10 mg dose in the morning on Day 8</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia Oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="80" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Salivary Hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="37" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="21" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator may not publish/publicly present interim results without prior consent of Sponsor. Any materials that report results of the study must be sent to Sponsor 45 days prior to submission for publication/presentation. Sponsor has right to review and comment. In case of any disagreements concerning appropriateness of the materials, investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues or disagreement, prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

